Request a Rep French Fr

BMS Patient Support Program has been designed to
complement your care — by offering you and your patients
customizable services.

BMS Patient Support Program
Enrolment Form

Enroll your patients to get started
with BMS Patient Support Program.

DOWNLOAD
Education

Information and tools for patients
and healthcare professionals.
From patient welcome kits
to risk management
support
to a dedicated Nurse
Case Manager to
respond
to their questions.
Convenience

Making the patient experience
easier
by offering a network
of infusion clinics
across Canada
and sharing
Patient Advocacy
Group information.
Connectivity

Keeping patients and
healthcare
professionals
connected with a dedicated
nurse case manager
and an immuno-oncology
bracelet for patients.
Support

Providing your patients
with personalized
services
based on evaluation of each
patient’s
unique support needs,
including psychological,
social
and educational needs to better tailor
the resources offered.
Access

Navigating
reimbursement coverage
and accelerating
access to treatment.

Please consult the OPDIVO Product Monograph
or click here for important information relating to:

  • The most serious warnings and precautions regarding severe/fatal immune-mediated adverse reactions (imARs), allogeneic hematopoietic stem cell transplantation (HSCT), multiple myeloma and administration under the supervision of physicians experienced in the treatment of cancer.
  • Other relevant warnings and precautions regarding frequency and signs and symptoms of imARs, infusion reaction, patients on controlled sodium diet, haemophagocytic lymphohistiocytosis (HLH), pregnancy, nursing and patients with moderate or severe hepatic or severe renal impairment.
  • Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions

Please consult the YERVOY Product Monograph
or click here for important information relating to:

  • The most serious warnings and precautions regarding severe/fatal immune-mediated adverse reactions (imARs) and administration under the supervision of physicians experienced in the treatment of cancer.
  • Other relevant warnings and precautions regarding frequency and signs and symptoms of imARs, patients who have had a severe or life-threatening skin adverse reaction on a prior cancer immune stimulatory therapy, haemophagocytic lymphohistiocytosis (HLH), Vogt-Koyanagi-Harada syndrome, serous retinal detachment, Graft-versus-host disease (GVHD), solid organ transplant rejection in the post-market setting, patients on immunosuppressive therapy for life-threatening disease or condition, autoimmune hemolytic anemia, myotoxicity (myositis, myocarditis, and rhabdomyolysis), patients on controlled sodium diet, concurrent administration with vemurafenib, patient counseling information: imARs and fatigue, hepatic impairment, renal impairment, pregnancy, nursing women and required close monitoring.
  • Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions